Selective inhibition of ALDH1A3 impedes breast cancer growth and metastasis by blocking ALDH1A3-driven...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Aldehyde dehydrogenase 1A3 (ALDH1A3) is implicated in tumor progression and chemoresistance in various cancers, notably triple-negative breast cancer (TNBC).
• Currently, there are no clinically approved inhibitors that selectively target ALDH1A3, representing a significant unmet need.

Purpose of the Study:

• To develop and characterize a novel, potent, and isoform-selective inhibitor of ALDH1A3.
• To evaluate the efficacy and safety of the ALDH1A3 inhibitor CLM296 in preclinical models of TNBC.

Main Methods:

• Development of CLM296, a rationally designed ALDH1A3 inhibitor.
• In vitro assays to determine ALDH1A3 inhibition and off-target effects.
• Transcriptomic analysis to confirm on-target activity.
• In vitro invasion assays and in vivo xenograft studies in TNBC models.
• Pharmacokinetic and toxicity assessments in preclinical models.

Main Results:

• CLM296 demonstrated nanomolar inhibition of ALDH1A3 in TNBC cells with high selectivity over ALDH1A1.
• Transcriptomic analysis confirmed CLM296 selectively suppressed ALDH1A3-driven gene expression.
• CLM296 significantly reduced ALDH1A3-dependent tumor growth and lung metastasis in vivo without observable toxicity.
• Pharmacokinetic studies showed favorable oral bioavailability and sustained target engagement in tissues.

Conclusions:

• CLM296 is a potent and selective ALDH1A3 inhibitor with promising preclinical efficacy against TNBC.
• The drug effectively targets ALDH1A3-driven tumor growth and metastasis.
• CLM296 exhibits favorable pharmacokinetic properties and a good safety profile, supporting its potential as a first-in-class therapeutic for ALDH1A3-positive cancers.